JP2024514956A - 組織標的化された改変aavカプシドおよびその使用方法 - Google Patents
組織標的化された改変aavカプシドおよびその使用方法 Download PDFInfo
- Publication number
- JP2024514956A JP2024514956A JP2023565273A JP2023565273A JP2024514956A JP 2024514956 A JP2024514956 A JP 2024514956A JP 2023565273 A JP2023565273 A JP 2023565273A JP 2023565273 A JP2023565273 A JP 2023565273A JP 2024514956 A JP2024514956 A JP 2024514956A
- Authority
- JP
- Japan
- Prior art keywords
- aav
- capsid protein
- amino acid
- seq
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178965P | 2021-04-23 | 2021-04-23 | |
| US63/178,965 | 2021-04-23 | ||
| US202263299697P | 2022-01-14 | 2022-01-14 | |
| US63/299,697 | 2022-01-14 | ||
| PCT/US2022/026048 WO2022226374A1 (en) | 2021-04-23 | 2022-04-22 | Tissue-targeted modified aav capsids and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514956A true JP2024514956A (ja) | 2024-04-03 |
| JP2024514956A5 JP2024514956A5 (cg-RX-API-DMAC7.html) | 2026-03-17 |
Family
ID=81598018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565273A Pending JP2024514956A (ja) | 2021-04-23 | 2022-04-22 | 組織標的化された改変aavカプシドおよびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240197918A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326868A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024514956A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216419A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226374A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025230000A1 (ja) * | 2024-05-01 | 2025-11-06 | Jcrファーマ株式会社 | 修飾されたaav粒子、その製造方法、関連する医薬及びその製造 |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12668814B2 (en) * | 2020-07-22 | 2026-06-30 | The Broad Institute, Inc. | Engineered muscle targeting compositions |
| KR20240095539A (ko) | 2021-10-08 | 2024-06-25 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 변이체 및 이의 사용 방법 |
| EP4353737A1 (en) * | 2022-10-10 | 2024-04-17 | Universitätsklinikum Hamburg-Eppendorf | Fusion proteins comprising a cell surface marker specific vhh |
| JP2026509271A (ja) | 2023-03-10 | 2026-03-17 | ダイノ セラピューティクス,インコーポレーテッド | カプシドポリペプチドおよびその使用方法 |
| CN118955652A (zh) * | 2023-05-15 | 2024-11-15 | 杭州新昶基因技术有限公司 | 腺相关病毒衣壳蛋白、包含其的腺相关病毒及应用 |
| AU2024271851A1 (en) * | 2023-05-16 | 2025-12-18 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| WO2025137378A1 (en) * | 2023-12-20 | 2025-06-26 | Aavantibio, Inc. | Aav capsid engineering for cardiac and/or musculoskeletal gene therapy |
| WO2025133247A1 (en) * | 2023-12-21 | 2025-06-26 | Genethon | Methods for aav vector re-administration |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| WO2025185625A1 (zh) * | 2024-03-04 | 2025-09-12 | 苏州新芽基因生物技术有限公司 | 特异性靶向人组织的多肽序列及其在构建递送载体中的应用 |
| WO2026064428A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064444A1 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026069251A1 (en) * | 2024-09-30 | 2026-04-02 | Sarepta Therapeutics, Inc. | Adeno-associated virus capsid antibodies and fragments thereof |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207132A1 (en) * | 2018-04-27 | 2019-10-31 | Universität Heidelberg | Modified aav capsid polypeptides for treatment of muscular diseases |
| WO2021000024A1 (en) * | 2019-07-04 | 2021-01-07 | Children's Medical Research Institute | Methods and aav vectors for in vivo transduction |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004514407A (ja) | 2000-04-28 | 2004-05-20 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター |
| WO2006076024A2 (en) * | 2004-05-14 | 2006-07-20 | University Of Miami | A method for targeting synapse with acetylcholinesterase |
| DE23193606T1 (de) * | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| CN101895633A (zh) | 2010-07-14 | 2010-11-24 | 中兴通讯股份有限公司 | 一种移动终端及其解锁方法 |
| US9580714B2 (en) | 2010-11-24 | 2017-02-28 | The University Of Western Australia | Peptides for the specific binding of RNA targets |
| CA2826273C (en) * | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| ES2751126T3 (es) | 2011-10-21 | 2020-03-30 | Univ Kyushu Nat Univ Corp | Método de diseño para proteína de unión a ARN usando motivo de PPR, y uso del mismo |
| US9434928B2 (en) | 2011-11-23 | 2016-09-06 | Nationwide Children's Hospital, Inc. | Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides |
| US10330674B2 (en) | 2015-01-13 | 2019-06-25 | Massachusetts Institute Of Technology | Pumilio domain-based modular protein architecture for RNA binding |
| CN111936621B (zh) * | 2018-02-05 | 2025-05-13 | 奥登茨治疗公司 | 转录调控元件和它的用途 |
| JP2022551986A (ja) * | 2019-10-16 | 2022-12-14 | ザ・ブロード・インスティテュート・インコーポレイテッド | 修飾筋肉標的化組成物 |
| US20230193316A1 (en) * | 2020-05-01 | 2023-06-22 | The Broad Institute, Inc. | Engineered central nervous system compositions |
| WO2022020616A1 (en) * | 2020-07-22 | 2022-01-27 | The Broad Institute, Inc. | Engineered muscle targeting compositions |
-
2022
- 2022-04-22 CA CA3216419A patent/CA3216419A1/en active Pending
- 2022-04-22 WO PCT/US2022/026048 patent/WO2022226374A1/en not_active Ceased
- 2022-04-22 US US18/287,963 patent/US20240197918A1/en active Pending
- 2022-04-22 JP JP2023565273A patent/JP2024514956A/ja active Pending
- 2022-04-22 EP EP22722646.1A patent/EP4326868A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019207132A1 (en) * | 2018-04-27 | 2019-10-31 | Universität Heidelberg | Modified aav capsid polypeptides for treatment of muscular diseases |
| WO2021000024A1 (en) * | 2019-07-04 | 2021-01-07 | Children's Medical Research Institute | Methods and aav vectors for in vivo transduction |
Non-Patent Citations (2)
| Title |
|---|
| OHNO KINJI ET AL.: "Roles of collagen Q in MuSK antibody-positive myasthenia gravis", CHEMICO-BIOLOGICAL INTERACTIONS, vol. 259, JPN6026019927, 24 April 2016 (2016-04-24), pages 266 - 270, ISSN: 0005869139 * |
| TRAJANOVSKA S. ET AL.: "Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss", THE JOURNAL OF PHYSIOLOGY, vol. 597, no. 18, JPN6026019926, 18 August 2019 (2019-08-18), pages 4831 - 4850, ISSN: 0005869140 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025230000A1 (ja) * | 2024-05-01 | 2025-11-06 | Jcrファーマ株式会社 | 修飾されたaav粒子、その製造方法、関連する医薬及びその製造 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240197918A1 (en) | 2024-06-20 |
| WO2022226374A1 (en) | 2022-10-27 |
| EP4326868A1 (en) | 2024-02-28 |
| CA3216419A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240197918A1 (en) | Tissue-targeted modified aav capsids and methods of use thereof | |
| JP7574508B2 (ja) | 血管系を通過する遺伝子移入の方法および組成物 | |
| US12584147B2 (en) | Rational polyploid adeno-associated virus vectors for the treatment of disease | |
| US11939597B2 (en) | Restrictive inverted terminal repeats for viral vectors | |
| US20250333763A1 (en) | Gene therapy constructs for treating wilson disease | |
| JP7406783B2 (ja) | パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質 | |
| WO2022226375A1 (en) | Tissue-targeted modified aav capsids and methods of use thereof | |
| JP7598333B2 (ja) | 組換えウイルスベクターの製造方法 | |
| CN117801075A (zh) | 多倍体腺相关病毒载体及其制备和使用方法 | |
| JP2021514659A (ja) | Aavキメラ | |
| EP4234571A2 (en) | Viral vectors with modified transduction profiles and methods of making and using the same | |
| KR20220009389A (ko) | 엑소좀 및 aav 의 조성물 | |
| CN111876432B (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
| CN110691846A (zh) | 合理的多倍体腺相关病毒载体及其制造和使用方法 | |
| KR20240095165A (ko) | 근이영양증의 치료 | |
| KR20250115422A (ko) | 반복적 요소의 적절한 패키징을 위한 아데노 연관 바이러스 벡터 | |
| WO2021167919A1 (en) | Aav capsid-promoter interactions and cell selective gene expression | |
| US20240271115A1 (en) | Methods and compositions for depleting antibodies | |
| HK40107364A (en) | Rational polyploid adeno-associated virus vectors and methods of making and using the same | |
| HK40016646A (en) | Rational polyploid adeno-associated virus vectors and methods of making and using the same | |
| HK40022719B (en) | Polyploid adeno-associated virus vectors and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250422 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250422 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20250422 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250805 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260526 |